In line with ROS production, these effects were attenuated by the 5-HT1BR inhibitor and the Nox1 inhibitor in hPASMCs, with additional inhibitory effects of SERT inhibitor, citalopram, in PAH-hPASMCs (Figure 4A). Here, SLC6A4 is linked to pulmonary arterial hypertension.